Showing results (101-110 of 131) with videos related to

Sort By:
Pageof 14
Transplantation|March 8, 2000
Attenuation of cytomegalovirus-induced endothelial intercellular adhesion molecule-1 mRNA/protein expression and T lymphocyte adhesion by a 2'-O-methoxyethyl antisense oligonucleotideD A Knight, B R Briggs, C F Bennett, et al.
Antisense & Nucleic Acid Drug Development|May 4, 2001
ADAM17 but not ADAM10 mediates tumor necrosis factor-alpha and L-selectin shedding from leukocyte membranesT P Condon, S Flournoy, G J Sawyer, et al.
Antisense & Nucleic Acid Drug Development|November 15, 1997
Characterization and modulation of immune stimulation by modified oligonucleotidesR T Boggs, K McGraw, T Condon, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 28, 2015
Historical Matching Strategies in Kidney Paired Donation: The 7-Year Evolution of a Web-Based Virtual Matching SystemD E Fumo, V Kapoor, L J Reece, et al.
Cancer Letters|July 4, 1998
Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alphaJ U Dennis, N M Dean, C F Bennett, et al.
Journal of Pharmaceutical Sciences|April 1, 1994
Lipid membrane permeability of 2'-modified derivatives of phosphorothioate oligonucleotidesJ A Hughes, C F Bennett, P D Cook, et al.
Trends in Pharmacological Sciences|March 1, 1989
The signal transduction system of the leukotriene D4 receptorS T Crooke, M Mattern, H M Sarau, et al.
Anti-Cancer Drug Design|February 1, 1993
Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expressionL Perlaky, Y Saijo, R K Busch, et al.
The Journal of Biological Chemistry|March 30, 2001
A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosisD D Bannerman, J C Tupper, W A Ricketts, et al.
Neurobiology of Disease|June 20, 2022
Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarksA Muinos-Bühl, R Rombo, E Janzen, et al.
Pageof 14